Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan Pfizer.

Paul J L M Strijbos1, Andrew A Parsons, Anders Fugelli

  • 1Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Avenue, Harlow, Essex, CM19 5AD, UK. Paul_J_Strijbos@GSK.com

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DYRK1a Inhibitor Mediated Rescue of <i>Drosophila</i> Models of Alzheimer's Disease-Down Syndrome Phenotypes.

Frontiers in pharmacology·2022
Same author

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus.

Antimicrobial agents and chemotherapy·2014
Same author

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.

Antimicrobial agents and chemotherapy·2012
Same author

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Experimental neurology·2008
Same author

Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.

The Journal of pharmacology and experimental therapeutics·2007

Eletriptan, a novel 5-HT1B/1D agonist developed by Pfizer, shows potential for migraine treatment. It exhibits higher receptor affinity compared to sumatriptan, suggesting enhanced efficacy for migraine patients.

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Development

Background:

  • Migraine is a debilitating neurological condition.
  • Current treatments include triptans, which target serotonin receptors.
  • There is a need for more effective migraine therapies.

Purpose of the Study:

  • To introduce eletriptan, a new 5-HT1B/1D agonist.
  • To compare the receptor binding affinity of eletriptan with existing triptans.
  • To evaluate the in vitro pharmacology of eletriptan.

Main Methods:

  • Pharmacological evaluation of eletriptan.
  • In vitro receptor binding assays.
  • Comparative analysis with sumatriptan, zolmitriptan, and naratriptan.

Related Experiment Videos

Main Results:

  • Eletriptan demonstrated a 6-fold greater affinity for the 5-HT1D receptor than sumatriptan.
  • Eletriptan showed a 3-fold greater affinity for the 5-HT1B receptor compared to sumatriptan.
  • In vitro pharmacology was assessed against zolmitriptan and naratriptan.

Conclusions:

  • Eletriptan possesses a distinct pharmacological profile with potentially improved receptor affinity.
  • These findings support the development of eletriptan for migraine treatment.
  • Further clinical evaluation is warranted to confirm efficacy and safety.